Global Autism Spectrum Disorder Therapeutics Market Analysis, Drivers, Restraints, Opportunities, Threats, Trends, Applications, and Growth Forecast to 2033
-
16071
-
May 2023
-
181
-
-
This report was compiled by Correspondence Linkedin | Detailed Market research Methodology Our methodology involves a mix of primary research, including interviews with leading mental health experts, and secondary research from reputable medical journals and databases. View Detailed Methodology Page
-
Global Autism Spectrum Disorder Therapeutics market size was valued at USD 2.2 billion in 2022 and is projected to grow USD 4.7 billion by 2033, growing at a CAGR of 7.2% during the forecast period 2022 to 2033.
“Global Autism Spectrum Disorder Therapeutics” is the title of an upcoming market research report at MarketResearch.biz. The market has been studied comprehensively to present vital data and information, including the revenue shares of each segment, region, and country, revenue growth driving factors, and restraints. In addition, potential revenue opportunities in untapped regions and economies are included. Key players and their details are presented in the company profile section of the report. The section comprises revenue and financial information and details, recent developments, strategies, acquisitions & mergers, as well as geographic reach and footprint. The global autism spectrum disorder therapeutics blood market is segmented by product type, treatment, and regions/countries.
Overview
Autism spectrum disorder can be defined as a set of neurological disorders that are manifested in an individual’s behavior which includes impaired communication and social interaction accompanied by a restricted or a repetitive pattern of activities and behaviors. These symptoms usually start developing at an early age and affect the functional abilities of autistic children in a social environment such as interacting or communicating with each other, etc. Pervasive development, Asperger syndrome, and autistic disorder are three common types of autism spectrum disorders that affect millions of individuals across the globe.
Dynamics
Rising incidences of autism spectrum disorder and the growing awareness about this condition and the available treatment options are among major factors that are contributing to this market’s growth. Currently, Aripiprazole and risperidone are the two available drugs in the market that have been approved by the Food and Drug Administration (FDA). Manufacturers are investing in research & development activities to increase the availability of drugs that can provide effective treatment solutions for autism spectrum disorders over the years to come. Moreover, the recent approval of various drugs by the FDA for autism disorder management purposes will lead to subsequent market growth in the foreseeable future.
The increase in investments by autism therapy services providers and a few government organizations to establish sufficient treatment facilities is expected to complement market growth. Few organizations are also investing in conducting programs that promote and provide behavioral health and education solutions to patients of autism spectrum disorder. In addition, policies of reimbursement to support treatment for the increasing number of autistic children are being introduced which will open several new avenues for market growth.
Global Autism Spectrum Disorder Therapeutics Market Segment Analysis
By Product Type: The autistic disorder segment is projected to continue to account for the majority revenue share when compared to the other segments due to the increasing prevalence of this type of disease.
By Treatment Type: The communication & behavioral therapy segment is expected to account for the majority revenue share in the coming years. The communication & behavioral therapy segment is further divided into applied behavior analysis therapies, speech & language therapies, and occupational therapies among others. The applied behavioral therapy segment is projected to account for the majority revenue share in the coming years. This is attributed to a surge in the demand for applied behavior analysis services due to its ability to provide effective solutions.
Regional Analysis:
The market in North America is expected to account for the majority revenue share over the next ten years. Increasing research & development activities and the launching of new products through mergers & strategic partnerships are among some of the key factors that are contributing to market growth in the region.
Furthermore, the introduction of reimbursement policies and the availability of adequate infrastructure & centers for autism treatment with special accessibility provided to children with autism spectrum disorder are expected to support market growth in the region.
The market in Europe is expected to account for the second-highest revenue share over the forecast period. This can be attributed to growing awareness about the availability of several therapies to treat patients with autism spectrum disorders.
Market Segmentation:
By Type
- Autistic Disorder
- Asperger Syndrome
- Pervasive Developmental Disorder
- Others
By Treatment Type
- Communication & Behavioral Therapies
- Applied behavior analysis (ABA)
- Speech & Language Therapy
- Occupational Therapy
- Others
- Drug Therapies
- Antipsychotic Drugs
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Stimulants
- Sleep Medications
- Others
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Attribute Report Details Market Size Ask For Market Size Growth Rate Ask For Growth Rate Key Companies Ask For Companies Report Coverage Revenue analysis, Competitive landscape, Key company analysis, Market Trends, Key segments, Distribution Channel, Market Dynamics, COVID-19 Impact Analysis and more… Historical Data Period 2015-2020 Base Year 2022 Forecast Period 2022-2031 Region Scope North America, Europe, Asia-Pacific, South America, Middle East & Africa Country Scope United States, Canada and Mexico, Germany, France, UK, Russia and Italy, China, Japan, Korea, India and Southeast Asia, Brazil, Argentina, Colombia etc.Saudi Arabia, UAE, Egypt, Nigeria and South Africa Revenue in US$ Mn -
-
- Allergan Q
- BioMed Inc
- Hopebridge LLC.
- Center for Autism and Related Disorders.
- Behavior Innovations
- Applied Behavior Consultants
- Fusion Autism Center
- Otsuka Holdings Co. Ltd.
- AstraZeneca
- Pfizer Inc.
- Eli Lilly and Company.
- Johnson & Johnson Services Inc.
Our Clients
View Our Licence Options
